Ultragenyx Pharmaceutical (RARE) AGM 2024 summary

Opening remarks and agenda

• The meeting was called to order by the Chairman, with all board members and key executives present.

• The agenda included voting on four proposals and a Q&A session with stakeholders.

Board and executive committee updates

• The board and executive team, including the CEO and Chief Legal Officer, were introduced and present for the meeting.

Shareholder proposals

• Four proposals were presented: reelection of three directors, approval of the Amended and Restated 2023 Incentive Plan, ratification of the independent auditor, and an advisory vote on executive compensation.